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Background:  In 2 prior studies, mipomersen (MIPO) 200 mg sc weekly reduced LDL-C in patients with homozygous and heterozygous familial 
hypercholesterolemia (HeFH) by 25% and 28% respectively when added to lipid-lowering therapies (LLT), including high dose statins. Patients with 
severe hypercholesterolemia (SH) often fail to normalize LDL-C despite potent LLT. This randomized, double-blind, placebo-controlled, multi-center 
phase 3 trial examined the safety and efficacy of MIPO in patients with SH, 90% of whom were HeFH.
Methods:  Adults (≥ 18 yrs) with LDL-C ≥300 mg/dL or LDL-C ≥200 mg/dL with coronary heart disease or other forms of clinical atherosclerotic 
disease on a maximally tolerated statin and at least one other class of LLT were enrolled. Patients continued prescribed LLT regimen and were 
randomized (2:1) to MIPO 200 mg s.c. weekly or placebo (PBO) for a 26-week period. The primary end point was percent reduction in LDL-C from 
baseline to week 28 or 2 weeks after the last dose for those not completing dosing.
Results:  Fifty-eight patients were randomized (39 MIPO, 19 PBO) at 26 clinical centers in 6 countries. Forty-five (78%) patients completed the 
treatment period. Eight (21%) Mipo and 1 (5%) PBO patient(s) withdrew due to an adverse event (AE). LDL-C was reduced by 36% from a mean 
baseline level of 276 mg/dL in the MIPO group vs. an increase of 13% from a BL of 249 mg/dL in the PBO group (p<0.001). This represents a 
>100 mg/dL mean reduction of LDL-C in the MIPO group. Similarly, MIPO produced highly significant (p<0.001) reductions in other atherogenic 
lipoproteins [e.g., apo B and Lp(a)]; there was no change in HDL-C. The most common on-treatment AEs were injection site reactions (90% MIPO, 
32% PBO) and flu-like symptoms (46% MIPO, 21% PBO). Six (15%) MIPO patients and no PBO patients had ALT ≥3 × ULN on consecutive measure at 
least 7 days apart. One MIPO patient had ALT ≥10 × ULN. ALT elevations were not associated with clinically significant increases in bilirubin.
Conclusions:  MIPO treatment reduced LDL-C and apoB significantly. The present data support the potential utility of MIPO as a pharmacologic 
option for additional LDL-C lowering in these patients not adequately controlled under existing LLTs.
